SUSAN J KIM
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology FAIRHAVEN, MA NPI 1891985990
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology MA Lilly USA, LLC All categories
General Payments — all program years on this page
$6,836.50
- Category: General Payments
- Program years: PY2018–2024
- Record count: 49
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,342.30 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,000.00 | 1 |
| Food and Beverage | $342.30 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $1,000.00 | 1 |
| Mirati Therapeutics, Inc. | $173.24 | 3 |
| Acerta Pharma LLC | $99.12 | 1 |
| GlaxoSmithKline, LLC. | $51.19 | 2 |
| Merck Sharp & Dohme Corporation | $18.75 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1104549456 | AstraZeneca Pharmaceuticals LP | $99.12 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1116270309 | GlaxoSmithKline, LLC. | $25.00 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1116396588 | GlaxoSmithKline, LLC. | $26.19 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1117177587 | Mirati Therapeutics, Inc. | $137.76 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1117177599 | Mirati Therapeutics, Inc. | $11.51 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1117177603 | Mirati Therapeutics, Inc. | $23.97 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1135425039 | Lilly USA, LLC | $1,000.00 | 03/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1141962754 | Merck Sharp & Dohme LLC | $18.75 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.